MA46204A - Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication - Google Patents
Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabricationInfo
- Publication number
- MA46204A MA46204A MA046204A MA46204A MA46204A MA 46204 A MA46204 A MA 46204A MA 046204 A MA046204 A MA 046204A MA 46204 A MA46204 A MA 46204A MA 46204 A MA46204 A MA 46204A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- manufacturing
- methods
- crystalline forms
- lysyl oxidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46204A true MA46204A (fr) | 2021-03-17 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046204A MA46204A (fr) | 2016-09-07 | 2017-09-06 | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (fr) |
| EP (1) | EP3510023B1 (fr) |
| JP (1) | JP7079772B2 (fr) |
| KR (1) | KR102587178B1 (fr) |
| CN (1) | CN109983006B (fr) |
| AU (1) | AU2017324445A1 (fr) |
| BR (1) | BR112019004517A2 (fr) |
| CA (1) | CA3036064A1 (fr) |
| EA (1) | EA201990621A1 (fr) |
| IL (1) | IL265192A (fr) |
| MA (1) | MA46204A (fr) |
| MX (1) | MX2019002615A (fr) |
| SG (1) | SG11201901999XA (fr) |
| WO (1) | WO2018048943A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144702A1 (fr) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| EP3795568A1 (fr) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Inhibiteurs fluorés de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| US10588900B2 (en) | 2016-02-09 | 2020-03-17 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| CN117180280A (zh) | 2016-09-07 | 2023-12-08 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的用途 |
| BR112019004517A2 (pt) * | 2016-09-07 | 2019-08-13 | Pharmakea Inc | formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| AP2002002583A0 (en) | 2000-01-18 | 2002-09-30 | Pfizer Prod Inc | Corticotropin releasing factor antagonists. |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| SI1638551T1 (sl) | 2003-05-19 | 2012-04-30 | Irm Llc | Imunosupresivne spojine in sestavki |
| WO2007016784A1 (fr) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Nouveau 1,2,3-tπazolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu’inhibiteurs de biosynthèse leukotπène |
| BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| DE602005022572D1 (de) | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| EP1735268B1 (fr) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Antagonistes des recepteurs opioides |
| ES2389907T3 (es) | 2004-04-30 | 2012-11-02 | Takeda Pharmaceutical Company Limited | Compuesto de amida heterocíclica y uso del mismo como un inhibidor de MMP-13 |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| US20080318926A1 (en) | 2004-09-10 | 2008-12-25 | Pfizer Inc | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives |
| EP1791540A2 (fr) | 2004-09-10 | 2007-06-06 | Pfizer Products Incorporated | Methodes destinees a traiter des troubles cognitifs au moyen de derives azabicycliques de pyridyloxymethyle et de benzisoxazole |
| US20080004269A1 (en) | 2004-11-04 | 2008-01-03 | Yuelian Xu | Pyrazolylmethy Heteroaryl Derivatives |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| WO2006083781A1 (fr) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Composes bicycliques antidiabetiques |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| JP2009523820A (ja) | 2006-01-23 | 2009-06-25 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼの三環系抑制剤 |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| JP2010501553A (ja) | 2006-08-18 | 2010-01-21 | アストラゼネカ アクチボラグ | Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体 |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| CN105330743B (zh) | 2007-08-02 | 2019-05-28 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| RU2012107163A (ru) | 2009-07-28 | 2013-09-10 | Анакор Фармасьютикалз, Инк. | Тризамещенные борсодержащие молекулы |
| BR112012008084A2 (pt) | 2009-08-21 | 2019-09-24 | Gilead Biologics Inc | método terapêuticos e composições. |
| CN105622757A (zh) | 2010-02-04 | 2016-06-01 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法 |
| EP2542089B1 (fr) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| US9957271B2 (en) | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| CN104364235B (zh) | 2012-04-25 | 2017-07-04 | 拉夸里亚创药株式会社 | 作为ttx‑s阻断剂的酰胺衍生物 |
| SG11201503065PA (en) | 2012-10-30 | 2015-05-28 | Gilead Sciences Inc | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| WO2014098098A1 (fr) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | Dérivé d'amide hétérocyclique et médicament le contenant |
| JP2018522812A (ja) | 2014-08-05 | 2018-08-16 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | カスパーゼ−６のモジュレーター |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| MX2017010300A (es) | 2015-02-15 | 2017-12-04 | Hoffmann La Roche | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de canal receptor de potencial transitorio, subfamilia a, miembro 1(trpa1). |
| WO2016144702A1 (fr) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| EP3795568A1 (fr) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Inhibiteurs fluorés de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| CN117180280A (zh) | 2016-09-07 | 2023-12-08 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的用途 |
| BR112019004517A2 (pt) | 2016-09-07 | 2019-08-13 | Pharmakea Inc | formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação |
-
2017
- 2017-09-06 BR BR112019004517A patent/BR112019004517A2/pt unknown
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 MX MX2019002615A patent/MX2019002615A/es unknown
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active IP Right Grant
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/fr active Active
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 CA CA3036064A patent/CA3036064A1/fr active Pending
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/fr unknown
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532919A (ja) | 2019-11-14 |
| EA201990621A1 (ru) | 2019-09-30 |
| CA3036064A1 (fr) | 2018-03-15 |
| KR102587178B1 (ko) | 2023-10-06 |
| AU2017324445A1 (en) | 2019-04-11 |
| EP3510023A1 (fr) | 2019-07-17 |
| CN109983006A (zh) | 2019-07-05 |
| EP3510023B1 (fr) | 2024-06-19 |
| WO2018048943A1 (fr) | 2018-03-15 |
| KR20190052040A (ko) | 2019-05-15 |
| EP3510023A4 (fr) | 2020-03-18 |
| US11459309B2 (en) | 2022-10-04 |
| US10774069B2 (en) | 2020-09-15 |
| IL265192A (en) | 2019-05-30 |
| SG11201901999XA (en) | 2019-04-29 |
| MX2019002615A (es) | 2019-10-15 |
| CN109983006B (zh) | 2022-02-25 |
| JP7079772B2 (ja) | 2022-06-02 |
| US20200361901A1 (en) | 2020-11-19 |
| US20190202805A1 (en) | 2019-07-04 |
| BR112019004517A2 (pt) | 2019-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46204A (fr) | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication | |
| MA48779A (fr) | Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation | |
| DK3873903T3 (da) | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere | |
| MA52488A (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| MA45670A (fr) | Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome | |
| MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| DK3661921T3 (da) | Selektive hæmmere af nlrp3-inflammasom | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| DK3204015T3 (da) | Forbindelser og fremgangsmåder til inhibition af hao1-genekspression (hydroxysyre oxidase 1 (glycolat oxidase)) | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| MA42055A (fr) | Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci | |
| DK3220741T3 (da) | Sammensætning og kits til hæmning af patogen mikrobiel infektion og fremgangsmåder til anvendelse af samme | |
| MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| MA55716A (fr) | Inhibiteurs de dihydroorotate déshydrogénase | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
| MA43271A (fr) | Formulations améliorées de déférasirox et leurs procédés de fabrication | |
| MA48793A (fr) | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 | |
| MA55477A (fr) | Inhibiteurs de hpk1 | |
| DK3481819T3 (da) | Forbindelser og anvendelse deraf til reducering af urisyreniveauer | |
| SG11202008925VA (en) | Inhibitors of micro-rna 22 | |
| DK3833665T3 (da) | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser | |
| DK3240767T3 (da) | Mikroindkapslede nitrifikationshæmmersammensætninger | |
| DK3137437T3 (da) | Mikroindkapslet nitrifikationsinhibitorsammensætning | |
| DK3837256T3 (da) | Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere |